查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842340

美國甲狀腺癌診斷市場：市場規模、佔有率、趨勢分析（按癌症類型、技術、最終用途和地區分類）、細分市場預測（2025-2033 年）

U.S. Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

據估計，2024 年美國甲狀腺癌診斷市值為 10.2 億美元，預計到 2033 年將達到 14.8 億美元，2025 年至 2033 年的複合年成長率約為 4.30%。

美國的甲狀腺癌診斷正在迅速發展，預計到2025年將新增44,020例病例，死亡2,290例。該疾病在女性中更為常見，通常在較年輕時確診，且在黑人人群中的發生率較低。過去幾十年，影像學檢查導致的過度診斷使得甲狀腺癌發生率持續上升，但自2014年以來，更嚴格的診斷標準已使發病率每年下降2%。基因組學、人工智慧輔助影像學和分子檢測技術的進步，使得精準醫療成為可能，從而減少了過度治療，並改善了侵襲性亞型的治療效果。

在美國，甲狀腺癌的診斷正迅速發展，受到發病率趨勢、風險因素以及分子檢測技術進步的影響。美國癌症協會預測，2025年，美國新患者（男性12,670例，女性31,350例），死亡2,290例，且確診年齡通常較年輕（平均51歲）。女性患病的可能性約為男性的三倍，而黑人患病的可能性比其他族裔低40%至50%。過去40年間，甲狀腺癌的發生率顯著上升，這主要是由於高靈敏度影像檢查的廣泛應用，這些檢查能夠檢測出體積小、局限性強的腫瘤，且這些腫瘤的生存率極高，但其中很大一部分是過度診斷。自2014年以來，更嚴格的診斷標準減少了過度診斷，使得甲狀腺癌的發生率每年下降2%，而死亡率自2009年以來一直保持穩定。

與這些趨勢相伴隨的是，一些重要的病因發現也逐漸浮現。歷史上，兒童時期的輻射暴露是唯一可改變的風險因素，但現在肥胖已被公認為一個重要的促成因素。此外，內分泌干擾物和甲狀腺功能障礙在疾病發展中的作用也正在被探索。重要的是，基因和分子譜分析已經識別出一些具有預後意義的突變，例如BRAFV600E、RAS、RET和NTRK，這些突變為精準治療提供了標靶。這些發現不僅加深了我們對疾病的理解，而且透過將分子檢測和新一代次世代定序儀整合到切片檢查評估中，實現了對良性和惡性結節的更佳鑑別，從而重塑了診斷方法。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章美國甲狀腺癌診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國甲狀腺癌診斷市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第4章美國甲狀腺癌診斷市場：按癌症類型分類的商業分析

  • 癌症專屬儀錶板
  • 甲狀腺癌診斷市場：按癌症類型分類的波動分析
  • 美國甲狀腺癌診斷市場規模及趨勢分析（按癌症類型分類）（2021-2033 年）
  • 乳頭狀癌
  • 濾泡癌
  • 其他

第5章美國甲狀腺癌診斷市場：按技術分類的業務分析

  • 技術專用儀錶板
  • 甲狀腺癌診斷市場：依技術分類的差異分析
  • 美國甲狀腺癌診斷市場規模及技術趨勢分析（2021-2033）
  • 血液檢查
  • 影像
  • 切片檢查
  • 其他

第6章美國甲狀腺癌診斷市場：按最終用途分類的業務分析

  • 按最終用戶分類的儀表板
  • 甲狀腺癌診斷市場：依最終用途分類的差異分析
  • 美國甲狀腺癌診斷市場規模及趨勢分析（按最終用途分類）（2021-2033 年）
  • 醫院檢查室
  • 癌症診斷中心
  • 研究所
  • 其他

第7章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要企業熱力圖分析（2024 年）
  • 公司簡介
    • Abbott
    • F.Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific, Inc.
    • Siemens Healthcare GmbH
    • Bio-Rad Laboratories, Inc.
    • GE HealthCare
    • Hologic, Inc.
    • Koninklijke Philips NV
    • Toshiba Corporation
    • Agilent Technologies, Inc.
    • Illumina, Inc.
Product Code: GVR-4-68040-728-1

Market Size & Trends:

The U.S. thyroid cancer diagnostics market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 1.48 billion by 2033, growing at a CAGR of around 4.30% from 2025 to 2033. Thyroid cancer diagnostics in the U.S. are rapidly evolving, with 2025 estimates projecting 44,020 new cases and 2,290 deaths. The disease is more common in women, often diagnosed at a younger age, and less prevalent among Black populations. While incidence rose for decades due to overdiagnosis from imaging, stricter criteria have reduced rates by 2% annually since 2014. Advances in genomics, AI-driven imaging, and molecular testing now enable precision medicine, reduce overtreatment, and improve outcomes for aggressive subtypes.

Thyroid cancer diagnostics in the United States are evolving rapidly, shaped by changing incidence trends, risk factors, and advances in molecular tools. In 2025, the American Cancer Society projects about 44,020 new cases (12,670 in men and 31,350 in women) and 2,290 deaths, with diagnosis typically occurring at a younger age (average 51 years). The disease is nearly three times more common in women than in men and is about 40-50% less common among Black populations compared to other groups. Over the past four decades, incidence rose dramatically, largely due to widespread use of sensitive imaging tests that detected small, localized tumors with excellent survival rates-many of which represented overdiagnosis. Since 2014, stricter diagnostic criteria have helped reduce overdiagnosis, leading to a 2% annual decline in incidence, while mortality has remained stable since 2009.

Key etiological insights have emerged alongside these trends. Historically, childhood radiation exposure was the only modifiable risk factor; however, obesity has now been recognized as a major contributor, though its biological mechanisms are not fully understood. Research is also examining the role of endocrine-disrupting chemicals and thyroid dysfunction in disease development. Importantly, genetic and molecular profiling has identified critical mutations-such as BRAFV600E, RAS, RET, and NTRK-that are both prognostic and predictive, offering targets for precision therapies. These discoveries have not only improved disease understanding but have also reshaped diagnostics by integrating molecular assays and next-generation sequencing into biopsy evaluation, allowing better differentiation between benign and malignant nodules.

U.S. Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. thyroid cancer diagnostics market report based on cancer, technique, end use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
    • Papillary carcinoma
    • Follicular carcinoma
    • Others
  • Technique Outlook (Revenue, USD Million, 2021 - 2033)
    • Blood Test
    • Imaging
    • Biopsy
    • Others
  • End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)
    • Hospital Laboratories
    • Cancer Diagnostic Centers
    • Research Institutes
    • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technique
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer Outlook
    • 2.2.2. Technique Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Thyroid Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Thyroid Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. U.S. Thyroid Cancer Diagnostics Market: Cancer Business Analysis

  • 4.1. Cancer Segment Dashboard
  • 4.2. Thyroid Cancer Diagnostics Market: Cancer Movement Analysis
  • 4.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Cancer, 2021 to 2033 (USD Million)
  • 4.4. Papillary carcinoma
    • 4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 4.5. Follicular carcinoma
    • 4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Thyroid Cancer Diagnostics Market: Technique Business Analysis

  • 5.1. Technique Segment Dashboard
  • 5.2. Thyroid Cancer Diagnostics Market: Technique Movement Analysis
  • 5.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Technique, 2021 to 2033 (USD Million)
  • 5.4. Blood Test
    • 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.5. Imaging
    • 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.6. Biopsy
    • 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Thyroid Cancer Diagnostics Market: End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Thyroid Cancer Diagnostics Market: End Use Movement Analysis
  • 6.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
  • 6.4. Hospital Laboratories
    • 6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.5. Cancer Diagnostic Centers
    • 6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.6. Research Institutes
    • 6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Abbott
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. F.Hoffmann-La Roche Ltd.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Thermo Fisher Scientific, Inc.
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Siemens Healthcare GmbH
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Bio-Rad Laboratories, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. GE HealthCare
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Hologic, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Koninklijke Philips N.V.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Toshiba Corporation
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Agilent Technologies, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Illumina, Inc.
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Abbreviations
  • Table 2 U.S. Thyroid Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 3 U.S. Thyroid Cancer Diagnostics Market, By Technique, 2021 - 2033 (USD Million)
  • Table 4 U.S. Thyroid Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Thyroid Cancer Diagnostics Market: Market Outlook
  • Fig. 10 Thyroid Cancer Diagnostics Competitive Insights
  • Fig. 11 Parent Market Outlook
  • Fig. 12 Related/Ancillary Market Outlook
  • Fig. 13 Penetration and Growth Prospect Mapping
  • Fig. 14 Industry Value Chain Analysis
  • Fig. 15 Thyroid Cancer Diagnostics Market Driver Impact
  • Fig. 16 Thyroid Cancer Diagnostics Market Restraint Impact
  • Fig. 17 Thyroid Cancer Diagnostics Market Strategic Initiatives Analysis
  • Fig. 18 Thyroid Cancer Diagnostics Market: Cancer Movement Analysis
  • Fig. 19 Thyroid Cancer Diagnostics Market: Cancer Outlook and Key Takeaways
  • Fig. 20 Papillary Carcinoma Market Estimates and Forecast, 2021 - 2033
  • Fig. 21 Follicular Carcinoma Market Estimates and Forecast, 2021 - 2033
  • Fig. 22 Others Market Estimates and Forecast, 2021 - 2033
  • Fig. 23 Thyroid Cancer Diagnostics Market: Technique Movement Analysis
  • Fig. 24 Thyroid Cancer Diagnostics Market: Technique Outlook and Key Takeaways
  • Fig. 25 Blood Test Market Estimates and Forecast, 2021 - 2033
  • Fig. 26 Imaging Market Estimates and Forecast, 2021 - 2033
  • Fig. 27 Biopsy Market Estimates and Forecast, 2021 - 2033
  • Fig. 28 Others Market Estimates and Forecast, 2021 - 2033
  • Fig. 29 Thyroid Cancer Diagnostics Market: End Use Movement Analysis
  • Fig. 30 Thyroid Cancer Diagnostics Market: End Use Outlook and Key Takeaways
  • Fig. 31 Hospital Laboratories Market Estimates and Forecasts, 2021 - 2033
  • Fig. 32 Cancer Diagnostic Centers Market Estimates and Forecasts, 2021 - 2033
  • Fig. 33 Research Institutes Market Estimates and Forecasts, 2021 - 2033
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033
  • Fig. 35 U.S. Market Estimates and Forecasts, 2021 - 2033